These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 6179159

  • 1. Consecutive, multimodal therapy of cancer: selective biological initiation (OK-432), cytoplasmic and nuclear damage (FT-207 and cyclophosphamide), inhibition of repair (bleomycin), and activation of cleansing and surveillance mechanisms.
    Okuyama S, Mishina H.
    Sci Rep Res Inst Tohoku Univ Med; 1981 Dec; 28(1-4):7-14. PubMed ID: 6179159
    [No Abstract] [Full Text] [Related]

  • 2. Immuno-chemotherapy of malignant lymphoma using OK-432, a streptococcal agent.
    Kimura I, Ohnoshi T, Nakata Y, Takasugi K, Fujii M, Hayashi K, Kataoka M, Sato M, Nishihara R.
    Acta Med Okayama; 1979 Dec; 33(6):471-8. PubMed ID: 94239
    [Abstract] [Full Text] [Related]

  • 3. [Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432].
    Kan N, Inamoto T, Hori T, Nio Y, Tsuchitani T, Kodama H, Tobe T, Ohgaki K.
    Nihon Gan Chiryo Gakkai Shi; 1985 May 20; 20(4):784-96. PubMed ID: 3877129
    [No Abstract] [Full Text] [Related]

  • 4. [A combined immuno-chemotherapy with futraful and picibanil for advanced cancer (author's transl)].
    Sawai K, Sonoda Y, Ohkuma S, Misawa S, Takino T.
    Nihon Gan Chiryo Gakkai Shi; 1977 Sep 20; 12(3):328-35. PubMed ID: 335004
    [No Abstract] [Full Text] [Related]

  • 5. [Experimental study on the effectiveness of BRM in radiation therapy--OK-432 and cyclophosphamide].
    Norimura T, Kunugita N, Dohi S, Mukae S, Tsuchiya T.
    Gan No Rinsho; 1988 Oct 20; 34(13):1811-5. PubMed ID: 3199515
    [Abstract] [Full Text] [Related]

  • 6. Principia of cancer therapy. III. Perpetuation principle of repairable chemotherapeutic damage: cisplatin-bleomycin in vitro.
    Okuyama S, Mishina H.
    Sci Rep Res Inst Tohoku Univ Med; 1983 Dec 20; 30(1-4):5-7. PubMed ID: 6205446
    [No Abstract] [Full Text] [Related]

  • 7. [Experimental studies on specific active immunotherapy using immune responses of irradiated tumor tissue. 4. Effects of a combined use of a non-specific immunopotentiator, OK-432].
    Imanaka K, Ogawa Y, Gose K, Imajo Y, Kimura S.
    Nihon Gan Chiryo Gakkai Shi; 1982 Aug 20; 17(5):1299-304. PubMed ID: 7153621
    [No Abstract] [Full Text] [Related]

  • 8. [Experimental studies on specific active immunotherapy using immune response of irradiated tumor tissues. 5. A combined effect of the immune response of cryopreserved tissue and OK-432].
    Ogawa Y, Imanaka K, Gose K, Imajo Y, Kimura S.
    Nihon Gan Chiryo Gakkai Shi; 1982 Aug 20; 17(5):1305-10. PubMed ID: 7153622
    [No Abstract] [Full Text] [Related]

  • 9. [A study of the synergy of microwave coagulation and streptococcal preparation (OK-432) in experimental tumors in relation to interleukin 2 producing activity].
    Yamaue H, Katsumi M, Tabuse K, Tabuse Y, Egawa H, Noguchi H, Nagai Y, Kobayashi Y, Mori K.
    Nihon Geka Hokan; 1986 Sep 01; 55(5):689-99. PubMed ID: 3495246
    [No Abstract] [Full Text] [Related]

  • 10. Studies on the host-mediated action of the streptococcal preparation, OK-432, in cancer chemotherapy.
    Kimura I, Onoshi T, Yasuhara S, Watanabe T, Sugiyama M, Hiraki K.
    Acta Med Okayama; 1974 Dec 01; 28(6):423-31. PubMed ID: 4142361
    [No Abstract] [Full Text] [Related]

  • 11. [Chemotherapy of experimental meningeal carcinomatosis (author's transl)].
    Shimizu K, Ushio Y, Hayakawa T, Ikeda H, Mogami H.
    No To Shinkei; 1979 Mar 01; 31(3):323-30. PubMed ID: 87211
    [No Abstract] [Full Text] [Related]

  • 12. [Immunochemotherapy of resectable lung cancer--a preliminary study on a comparison of the control, levamisole, and OK-432].
    Okayasu T, Kashimura Y, Matano J, Kawabata M, Takeoka T, Hashimoto M, Tanabe T.
    Gan To Kagaku Ryoho; 1982 Sep 01; 9(9):1646-52. PubMed ID: 6764120
    [Abstract] [Full Text] [Related]

  • 13. [Thermotherapy for cancer of the urinary bladder in combination with tegafur and picibanil--with special reference to the serum bladder and bladder cancer tissue concentrations of tegafur in a perfusion fluid].
    Murahashi I, Kanbe K, Kaneko K, Honda M, Maeda S, Takahashi E.
    Gan To Kagaku Ryoho; 1984 Sep 01; 11(9):1781-8. PubMed ID: 6433803
    [Abstract] [Full Text] [Related]

  • 14. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T, Harada M, Yamada A, Tanaka M, Takao Y, Tanaka Y, Mine T, Sakamoto K, Nakashima T, Itoh K.
    Clin Cancer Res; 2006 Feb 15; 12(4):1325-32. PubMed ID: 16489090
    [Abstract] [Full Text] [Related]

  • 15. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
    Hashimoto M, Takashige K, Furuyashiki M, Yoshidome K, Sano R, Kawamura Y, Ijichi S, Morioka H, Koide H, Oku N, Moriya Y, Kusumoto S, Suda Y.
    Int Immunopharmacol; 2008 Jan 15; 8(1):12-9. PubMed ID: 18068095
    [Abstract] [Full Text] [Related]

  • 16. [Anti-tumor effect of intratumoral administration of dendritic cells in combination with TS-1 and OK-432].
    Okamoto M, Ahmed SU, Oshikawa T, Tano T, Sato M.
    Gan To Kagaku Ryoho; 2004 Oct 15; 31(11):1627-30. PubMed ID: 15553665
    [Abstract] [Full Text] [Related]

  • 17. Selective response of DNA polymerase beta to bleomycin-induced breaks in DNA.
    Coetzee ML, Chou R, Ove P.
    Cancer Res; 1978 Nov 15; 38(11 Pt 1):3621-7. PubMed ID: 81104
    [No Abstract] [Full Text] [Related]

  • 18. Does OK-432 selectively increase bleomycin concentration in tumor?
    Okuyama S, Mishina H, Matsuzawa T.
    Gan; 1979 Jun 15; 70(3):385-6. PubMed ID: 89059
    [No Abstract] [Full Text] [Related]

  • 19. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M.
    Cancer Res; 2004 Aug 01; 64(15):5461-70. PubMed ID: 15289356
    [Abstract] [Full Text] [Related]

  • 20. [A case of blastic crisis of chronic myelogenous leukemia with good response to the streptococcal agent OK-432 (author's transl)].
    Fujii H.
    Rinsho Ketsueki; 1977 Nov 01; 18(11):1336-42. PubMed ID: 271750
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.